Zhejiang Medicine Management
Management criteria checks 3/4
Zhejiang Medicine's CEO is Chun Lei Lu, appointed in Jun 2018, has a tenure of 6.5 years. directly owns 0.035% of the company’s shares, worth CN¥5.54M. The average tenure of the management team and the board of directors is 3.5 years and 3.5 years respectively.
Key information
Chun Lei Lu
Chief executive officer
CN¥2.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.5yrs |
| CEO ownership | 0.04% |
| Management average tenure | 3.5yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch
Nov 22
We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings
Nov 01Is Zhejiang Medicine (SHSE:600216) A Risky Investment?
Sep 14What Zhejiang Medicine Co., Ltd.'s (SHSE:600216) 27% Share Price Gain Is Not Telling You
Aug 06Zhejiang Medicine (SHSE:600216) Is Reducing Its Dividend To CN¥0.15
Jul 05The Market Doesn't Like What It Sees From Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Earnings Yet
Jun 21Zhejiang Medicine's (SHSE:600216) Earnings Are Weaker Than They Seem
May 02Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet
Mar 29CEO
Chun Lei Lu (57 yo)
6.5yrs
Tenure
CN¥2,844,200
Compensation
Mr. Chun Lei Lu is President and Director of Zhejiang Medicine Co., Ltd. since June 15, 2018. He serves as Vice Chairman of Zhejiang Medicine Co., Ltd.since June 16, 2021. Mr. Lu was Executive Vice Presid...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Vice Chairman | 6.5yrs | CN¥2.84m | 0.035% CN¥ 5.5m | |
| Executive Vice President | 6.5yrs | CN¥2.61m | 0.019% CN¥ 3.1m | |
| Vice President | 9.5yrs | CN¥2.05m | 0.042% CN¥ 6.5m | |
| Vice President | 3.5yrs | CN¥1.90m | 0.0052% CN¥ 815.1k | |
| Senior Manager | 3.5yrs | CN¥2.24m | no data | |
| Senior Manager | 3.5yrs | CN¥1.97m | 0.0078% CN¥ 1.2m | |
| Senior Manager | 3.5yrs | CN¥2.10m | 0.0052% CN¥ 815.1k | |
| Vice Chairman & Vice President | 6.5yrs | CN¥2.86m | 0.12% CN¥ 18.2m | |
| CFO & Financial Director | 3.5yrs | CN¥1.22m | 0.0052% CN¥ 815.1k | |
| Accounting Supervisor | no data | no data | no data | |
| Board Secretary | 1.3yrs | no data | no data | |
| Vice President | 9.5yrs | CN¥1.82m | 0.036% CN¥ 5.7m |
3.5yrs
Average Tenure
50yo
Average Age
Experienced Management: 600216's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Vice Chairman | 12.5yrs | CN¥2.84m | 0.035% CN¥ 5.5m | |
| Vice Chairman & Vice President | 6.5yrs | CN¥2.86m | 0.12% CN¥ 18.2m | |
| Chairman of the Board | 21.5yrs | CN¥3.46m | 0.0097% CN¥ 1.5m | |
| Independent Director | 6.5yrs | CN¥120.00k | no data | |
| Independent Director | 3.5yrs | CN¥120.00k | no data | |
| Director | 3.5yrs | CN¥1.86m | 0.0078% CN¥ 1.2m | |
| Director | 3.5yrs | CN¥1.85m | 0.0052% CN¥ 815.1k | |
| Independent Director | 3.5yrs | CN¥120.00k | no data | |
| Independent Director | 3yrs | CN¥120.00k | no data | |
| Vice Chairman | 1.5yrs | no data | no data | |
| Chief Supervisor | 1.5yrs | no data | no data | |
| Director | 1.5yrs | no data | no data |
3.5yrs
Average Tenure
48.5yo
Average Age
Experienced Board: 600216's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 07:26 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Medicine Co., Ltd. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaofeng Qiu | China International Capital Corporation Limited |
| Yilin Hou | China International Capital Corporation Limited |
| Zheng Zhou | China Merchants Securities Co. Ltd. |